Gyre Therapeutics, Inc. (GYRE)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 21 | 7 | 102 | 113 | 106 | 117 | 119 | 110 |
| Operating profit | $m | 11 | -17 | ||||||
| Net profit | $m | -56 | -88 | 2 | -93 | 12 | 5 | -17 | -41 |
| EPS reported | $ | 0.02 | -0.20 | ||||||
| Operating cashflow per share | $ | 0.01 | -0.14 | ||||||
| Capex per share | $ | 0.01 | 0.02 | ||||||
| FCF per share | $ | -0.00 | -0.17 | ||||||
| Free cash flow | $m | -0 | -17 | ||||||
| Net debt | $m | -52 | -75 | ||||||
| Book value equity | $m | 106 | 130 | ||||||
| Book value per share | $ | 1.03 | 1.30 | ||||||
| Number of shares | m | 103.18 | 100.64 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 313.78 | - | ||||||
| P/B LTM | x | 5.95 | 4.84 | ||||||
| P/S LTM | x | 5.41 | 5.28 | ||||||
| P/FCF LTM | x | -3,504.29 | -37.57 | ||||||
| EV/EBITDA LTM | x | 35.07 | -42.40 | ||||||
| EV/Sales LTM | x | 5.10 | 5.90 | ||||||
| Earnings Yield LTM | % | +0.32% | -2.58% | ||||||
| FCF Yield | % | -0.03% | -2.66% | ||||||
| Quality | |||||||||
| ROE | % | +4.74% | -15.77% | ||||||
| ROIC | % | +5.30% | -9.69% | ||||||
| Operating margin | % | +9.86% | -13.97% | ||||||
| Gross margin | % | +95.35% | +94.30% | ||||||
| FCF/Sales | % | -0.15% | -14.06% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -55.00% | - | ||||||
| Sales Growth YoY | % | +10.24% | +12.88% | ||||||
| Net Income Growth YoY | % | -58.40% | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | -29.19% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.19 | -4.91 | ||||||
| Net Debt/EBITDA | x | -2.13 | 2.84 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.49 | -0.57 | ||||||
| Gross debt/equity | x | 0.01 | 0.03 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free